 PHILADELPHIA, Feb. 19, 2021 GLOBE NEWSWIRE -- Passage Bio, Inc. Nasdaq: PASG, a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system CNS disorders, today announced the appointment of Maxine Gowen, Ph.D., to its board of directors, effective Feb. 18. Dr. Gowen is chief executive officer of Tamuro Bio, a post that she has held since July 2019. 